Microcap Ledger

Tickers · $TENX

Tenax Therapeutics, Inc. $TENX

By Microcap Ledger desk · CIK 0000034956

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Capital Market
Sector
Pharmaceutical Preparations
Headquarters
Chapel Hill, NC
Fiscal year end
December 31
Shares outstanding
37,423,917 [10-Q 2026-07-31]
as of 2026-07-28

Sources: [10-K 2026-03-10]

What the company doesAI summary of filing

Tenax Therapeutics is a clinical-stage pharmaceutical company developing novel cardiopulmonary therapies. The company is conducting two Phase 3 clinical trials (LEVEL and LEVEL-2) to evaluate oral levosimendan (TNX-103) for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), for which no FDA-approved therapies currently exist. The company also maintains a deprioritized program evaluating imatinib (TNX-201) for pulmonary arterial hypertension (PAH). Tenax generates no revenue and is pre-revenue, relying on clinical development funding to advance its product candidates toward regulatory approval and potential commercialization. [10-K 2026-03-10]

Segments: Oral levosimendan (TNX-103) for PH-HFpEF, Imatinib (TNX-201) for PAH

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026$0.00−$33.52M −$23.46M$118.00M[10-Q 2026-07-31]
FY ended Dec 2025$0.00−$52.60M −$35.80M$97.60M[10-K 2026-03-10]
FY ended Dec 2024$0.00−$17.60M −$14.81M$94.90M[10-K 2025-03-25]
Quarterly cash burn
−$11.73M
Cash runway Estimate
~30.2 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-10-313,408,906[10-Q 2024-11-13]
2025-03-213,970,385[10-K 2025-03-25]
2025-05-094,148,495[10-Q 2025-05-14]
2025-08-114,562,500[10-Q 2025-08-13]
2025-11-116,243,575[10-Q 2025-11-12]
2026-03-0617,197,613[10-K 2026-03-10]
2026-05-0826,525,159[10-Q 2026-05-12]
2026-07-2837,423,917[10-Q 2026-07-31]
Shelf registration
S-3 filed 2026-03-24; declared effective 2026-04-01 [S-3 2026-03-24]

Listing status

Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-09-16Doogan Declanbuy53,000$1.92[4 2026-09-17]
2026-09-15Giordano Christopher Thomasbuy4,850$1.82[4 2026-09-15]
2026-09-11Giordano Christopher Thomasbuy6,000$1.88[4 2026-09-15]
2026-09-11Staab Thomas R Iibuy5,675$1.94[4 2026-09-15]
2026-09-03Adar1 Capital Management, Llcbuy900,000$1.78[4 2026-09-08]
2026-09-02Adar1 Capital Management, Llcbuy187,704$1.80[4 2026-09-02]
2026-09-01Adar1 Capital Management, Llcbuy179,058$1.80[4 2026-09-02]
2026-08-31Adar1 Capital Management, Llcbuy403,571$1.79[4 2026-09-02]
2026-08-24Adar1 Capital Management, Llcbuy107,374$1.75[4 2026-08-24]
2026-08-21Adar1 Capital Management, Llcbuy716,369$1.77[4 2026-08-24]
2026-08-20Adar1 Capital Management, Llcbuy202,124$1.78[4 2026-08-24]
2026-07-13Giordano Christopher Thomasexercise219$3.55[4 2026-07-14]

Catalysts and calendar

Recent filings and releases
DateTypeTitle
2026-10-0913G/ABeneficial ownership report (5%+ holder)
2026-10-088-KOther events
2026-09-1113G/ABeneficial ownership report (5%+ holder)
2026-09-098-KRegulation FD disclosure
2026-09-0813GBeneficial ownership report (5%+ holder)
2026-09-0813G/ABeneficial ownership report (5%+ holder)
2026-08-2713GBeneficial ownership report (5%+ holder)
2026-08-2713GBeneficial ownership report (5%+ holder)
2026-08-1813GBeneficial ownership report (5%+ holder)
2026-08-1413G/ABeneficial ownership report (5%+ holder)
2026-08-1413G/ABeneficial ownership report (5%+ holder)
2026-08-1413G/ABeneficial ownership report (5%+ holder)

Facts as of . Small caps move fast; check the latest filings.